Vaxcyte Interest Income Over Time
| PCVX Stock | USD 93.98 2.53 2.77% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Vaxcyte Performance and Vaxcyte Correlation. Vaxcyte |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vaxcyte. If investors know Vaxcyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vaxcyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.60) | Return On Assets (0.15) | Return On Equity (0.21) |
The market value of Vaxcyte is measured differently than its book value, which is the value of Vaxcyte that is recorded on the company's balance sheet. Investors also form their own opinion of Vaxcyte's value that differs from its market value or its book value, called intrinsic value, which is Vaxcyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vaxcyte's market value can be influenced by many factors that don't directly affect Vaxcyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vaxcyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vaxcyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vaxcyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Interest Income Analysis
Compare Vaxcyte and related stocks such as Larimar Therapeutics, Syndax Pharmaceuticals, and Merus BV Interest Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LRMR | 473 K | 473 K | 473 K | 473 K | 473 K | 473 K | 347 K | 971 K | 246 K | 248 K | 248 K | 248 K | 248 K | 223.2 K | 365.6 K |
| SNDX | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 956 K | 1.4 M | 1.9 M | 1.6 M | 841 K | 403 K | 5.9 M | 18.6 M | 19.5 M |
| MRUS | 156.8 K | 156.8 K | 156.8 K | 156.8 K | 156.8 K | 156.8 K | 92.5 K | 1.3 M | 2.1 M | 1.9 M | 300 K | 2.7 M | 2.7 M | 3.1 M | 3.3 M |
| STRO | 251 K | 251 K | 251 K | 251 K | 251 K | 251 K | 251 K | 273 K | 1.6 M | 4.1 M | 1.5 M | 577 K | 3.5 M | 12.1 M | 12.7 M |
| ACLX | 59 K | 59 K | 59 K | 59 K | 59 K | 59 K | 59 K | 59 K | 59 K | 59 K | 59 K | 59 K | 4.3 M | 19.4 M | 20.3 M |
| VTYX | 78 K | 78 K | 78 K | 78 K | 78 K | 78 K | 78 K | 78 K | 78 K | 78 K | 78 K | 78 K | 4.7 M | 14.6 M | 15.4 M |
| IMCR | 822 K | 822 K | 822 K | 822 K | 822 K | 822 K | 822 K | 822 K | 822 K | 1.4 M | 706 K | 47 K | 3.2 M | 12.5 M | 13.1 M |
| NUVL | 4.3 M | 4.3 M | 4.3 M | 4.3 M | 4.3 M | 4.3 M | 4.3 M | 4.3 M | 4.3 M | 4.3 M | 4.3 M | 4.3 M | 4.3 M | 23.3 M | 15.1 M |
| VRDN | 403 K | 403 K | 403 K | 403 K | 403 K | 403 K | 403 K | 403 K | 1.3 M | 941 K | 173 K | 318 K | 4.9 M | 16.5 M | 17.3 M |
| LEGN | 6.2 M | 6.2 M | 6.2 M | 6.2 M | 6.2 M | 6.2 M | 6.2 M | 6.2 M | 6.2 M | 4.6 M | 2.9 M | 971 K | 8.2 M | 42.1 M | 44.2 M |
| APLS | 250.6 K | 250.6 K | 250.6 K | 250.6 K | 250.6 K | 250.6 K | 250.6 K | 250.6 K | 3 M | 5.1 M | 4.2 M | 418 K | 8.9 M | 20.9 M | 22 M |
| TVTX | 5.5 M | 5.5 M | 5.5 M | 5.5 M | 5.5 M | 5.5 M | 5.5 M | 5.5 M | 5.5 M | 10.1 M | 5 M | 2 M | 6.3 M | 21.8 M | 22.9 M |
| AKRO | 62.1 M | 62.1 M | 62.1 M | 62.1 M | 62.1 M | 62.1 M | 62.1 M | 62.1 M | 62.1 M | 109 K | 109 K | 109 K | 3.9 M | 24.2 M | 18.1 M |
| BMRN | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 7.5 M | 14.9 M | 22.8 M | 22.7 M | 16.6 M | 10.5 M | 18 M | 49 M | 51.5 M |
| LQDA | 14.9 K | 14.9 K | 14.9 K | 14.9 K | 14.9 K | 14.9 K | 14.9 K | 268 | 305 K | 613.7 K | 184.4 K | 33.4 K | 1.1 M | 3.2 M | 3.3 M |
| TECH | 7.8 M | 7.8 M | 7.8 M | 7.8 M | 7.8 M | 2.6 M | 304 K | 409 K | 569 K | 605 K | 473 K | 794 K | 3.4 M | 3.3 M | 3.5 M |
Vaxcyte and related stocks such as Larimar Therapeutics, Syndax Pharmaceuticals, and Merus BV Interest Income description
Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.My Equities
My Current Equities and Potential Positions
| Vaxcyte | PCVX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 93.98
Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.